Parenchymal imaging adds diagnostic utility in evaluating haematuria.

OBJECTIVE: To compare the findings of renal ultrasonography (US) in the evaluation of patients with and with no haematuria. The increased use of cross-sectional imaging and US has led to a dramatic improvement in the diagnosis of renal masses, such that computed tomography and/or US have been integrated into the diagnostic evaluation of haematuria, and many more incidental renal lesions are now detected. Thus it is possible that the lesions identified during evaluation for haematuria are incidental, i.e. identified serendipitously, and unrelated to the haematuria. PATIENTS AND METHODS: We retrospectively compared the US findings obtained from 301 patients referred for new-onset haematuria to those obtained from 600 patients being evaluated for other than urological reasons. All imaging and patient charts were reviewed to verify the clinical and radiological data. RESULTS: Haematuria was associated with all renal abnormalities, with an odds ratio (OR, 95% confidence interval) of 4.7 (3.6-7.3). Importantly, haematuria was associated with a renal mass, with an OR of 6.7 (2.8-16.3). Subset analysis revealed that patients with macroscopic and microscopic haematuria had significantly more renal abnormalities (OR 4.7, 2.7-8.2, and 5.3, 3.2-8.8, respectively) and renal masses (OR 7.3, 2.7-20.3, and 6.5, 2.3-18.6, respectively) than controls. CONCLUSIONS: Both macroscopic and microscopic haematuria are associated with a greater risk of identifying renal lesions. This supports the conclusion that the renal lesions identified with modern imaging techniques during the evaluation of both microscopic and macroscopic haematuria are not serendipitous.

Gadofosveset (EPIX/Schering).

EPIX Medical and Schering are developing gadofosveset, an albumin-binding gadolinium-based intravascular magnetic resonance imaging contrast agent, for the potential imaging of blood vessels and blood flow, particularly in patients with peripheral vascular disease (PVD). By February 2004, US approval of the agent was anticipated in October 2004, and in June 2004, Schering filed an MAA in the EU for PVD.

Adrenal masses: mr imaging features with pathologic correlation.

The detection of adrenal lesions has increased with the expanding use of cross-sectional imaging. Magnetic resonance (MR) imaging is often useful for characterizing adrenal masses. Adrenal masses can be classified into various groups on the basis of the presence of intracellular lipid, macroscopic fat, hemorrhage, and cystic changes and the vascularity and shape of the tumor. These imaging features can be used by the radiologist to suggest or confirm a diagnosis for most adrenal masses, including adenoma, hyperplasia, simple and complicated cysts, lymphangioma, myelolipoma, pheochromocytoma, hemorrhage, cortical carcinoma, neuroblastoma, lymphoma, and metastases. Adenomas and metastases are common, and a decrease in signal intensity on out-of-phase images can be used to differentiate between them. Carcinoma is a possible diagnosis if that decrease in signal intensity is heterogeneous. Benign disease is diagnosed if macroscopic fat or a homogeneous cystlike lesion is seen. Recognition of the typical MR imaging features is important because it often changes the treatment approach and may obviate surgery.